Home › H3 Biomedicine Receives FDA Acceptance For Investigational New Drug Application
 

Keywords :   


H3 Biomedicine Receives FDA Acceptance For Investigational New Drug Application

2016-06-01 06:06:14| drugdiscoveryonline Home Page

H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of the Eisai Group, announced recently that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800

Tags: application drug acceptance receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
14.05The LOccitane Group Appoints Evelyne LY-Wainer Managing Director Global Travel Retail
14.05Recovery resources available for Texas livestock producers
14.05About-Face and AF94 Appoint Francesca Raminella as New CEO
14.05An unraveled genetic mystery in Angus
14.05Is HPAI a risk to beef cattle?
14.05Fresh Partners with Juno Shen on Limited-Edition Kombucha Facial Treatment Essence
More »